These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 34986617

  • 1. [Retrospective analysis of infliximab in the treatment of Kawasaki disease].
    Xie LP, Zhao L, Chu C, He L, Liang XC, Sun SN, Zhao QM, Wang F, Cao YY, Lin YX, Zeng ZQ, Wu L, Huang GY, Liu F.
    Zhonghua Er Ke Za Zhi; 2022 Jan 02; 60(1):14-19. PubMed ID: 34986617
    [Abstract] [Full Text] [Related]

  • 2. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease.
    Nagatomo Y, Muneuchi J, Nakashima Y, Nanishi E, Shirozu H, Watanabe M, Uike K, Nagata H, Hirata Y, Yamamura K, Takahashi Y, Okada S, Suzuki Y, Hasegawa S, Ohga S.
    Int J Cardiol; 2018 Nov 15; 271():317-321. PubMed ID: 30144998
    [Abstract] [Full Text] [Related]

  • 3. [Analysis of 2 diagnostic criteria of echocardiography for coronary artery aneurysm in Kawasaki disease].
    Liu WQ, Xia B, Fan W, Yu Z, Lin WL, Chen L, Wang C, Liu BN, Li J, Yang J.
    Zhonghua Er Ke Za Zhi; 2022 Jun 02; 60(6):588-593. PubMed ID: 35658368
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, Tremoulet AH.
    Arch Dis Child; 2023 Oct 02; 108(10):833-838. PubMed ID: 37258054
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
    Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
    J Pediatr; 2022 Jan 02; 240():158-163.e4. PubMed ID: 34461064
    [Abstract] [Full Text] [Related]

  • 10. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Jan 02; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
    Ansai H, Masuda H, Nakao H, Nishimura N, Kubota M.
    Pediatr Int; 2022 Jan 02; 64(1):e15226. PubMed ID: 35831245
    [Abstract] [Full Text] [Related]

  • 13. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
    Friedman KG, Gauvreau K, Baker A, Son MB, Sundel R, Dionne A, Giorgio T, De Ferranti S, Newburger JW.
    Arch Dis Child; 2021 Mar 02; 106(3):247-252. PubMed ID: 32943389
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.
    Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T, Committee of Survey on Infliximab use for Kawasaki diseaseJapan Society of Kawasaki Disease, Tokyo, Japan..
    J Pediatr; 2018 Apr 02; 195():115-120.e3. PubMed ID: 29224935
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
    Matsuoka R, Furuno K, Nanishi E, Onoyama S, Nagata H, Yamamura K, Sugitani Y, Kuraoka A, Mizuno Y, Sagawa K, Honjo S, Hara T, Ohga S.
    J Pediatr; 2020 Dec 02; 227():224-230.e3. PubMed ID: 32810506
    [Abstract] [Full Text] [Related]

  • 20. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.